BCWORLD PHARM. Co., Ltd.
Financials
Valuation Metrics
BCWORLD PHARM. Co., Ltd.'s Market Cap is ₩340B. At end of 2025 it was ₩588B. Ranked #1985 of 2,436 in KR market (top 81%), #1250 of 1,649 on KOSDAQ (top 76%), #213 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 91%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 33.97B KRW | KR#1,985/2,436 Sec#213/234 |
| Revenue | 79.81B KRW | KR#1,536/2,436 Sec#97/234 |
| Net Income | -481.4M KRW | KR—/2,436 Sec—/234 |
| Total Assets | 173.26B KRW | KR#1,374/2,436 Sec#106/234 |
| Net Assets | 72.36B KRW | KR#1,625/2,436 Sec#138/234 |
| Employees | 281 | KR#834/2,436 Sec#71/234 |
| Value | ||
| P/B | 0.47x | KR#742/2,436 Sec#26/234 |
| P/S | 0.43x | KR#810/2,436 Sec#24/234 |
| EV/EBITDA | 26.23x | KR#1,144/2,436 Sec#72/234 |
| Profitability | ||
| ROE | -0.67% | KR#1,545/2,436 Sec#107/234 |
| ROA | -0.28% | KR#1,523/2,436 Sec#107/234 |
| Op. Margin | 5.64% | KR#842/2,436 Sec#67/234 |
| Revenue Growth | 25.36% | KR#544/2,436 Sec#52/234 |
| Earnings Growth | -2216.81% | KR#1,727/2,436 Sec#120/234 |
| Financial Health | ||
| Debt Ratio | 239.44% | KR#1,950/2,436 Sec#209/234 |
| Total Debt | 87.53B KRW | KR#762/2,436 Sec#49/234 |
| Cash | 3.52B KRW | KR#2,115/2,436 Sec#196/234 |
| Current Ratio | 0.56x | KR#2,219/2,436 Sec#210/234 |
| Net Debt/EBITDA | 18.68x | KR#1,417/2,436 Sec#100/234 |
| Dividend | ||
| Div. Yield | 2.96% | KR#667/2,436 Sec#33/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -20.41% | KR#1,277/2,436 Sec#105/234 |
| 1M Return | 1.92% | KR#695/2,436 Sec#60/234 |
| From 52W High | -47.18% | KR#1,063/2,436 Sec#86/234 |
| 1Y MDD | -49.57% | KR#910/2,436 Sec#73/234 |
| Trading | ||
| Volume | 11,778 shares | KR#2,069/2,436 Sec#206/234 |
| Foreign Own. | 0.88% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -235 KRW | KR—/2,436 Sec—/234 |
| BPS | 6,916 KRW | KR#1,192/2,436 Sec#84/234 |
Company Info
BC World Pharm, established in 1980 and renamed in 2007, was certified as an innovative pharmaceutical company in 2012, a status it holds until 2024. The company specializes in pharmaceutical manufacturing and sales, leveraging EU GMP/cGMP-level facilities to expand its domestic and international Contract Manufacturing Organization (CMO)/Contract Development and Manufacturing Organization (CDMO) businesses and exports to advanced and emerging markets. As an R&D-focused pharmaceutical company with original Drug Delivery System (DDS) technology, it invests about 12% of its sales into R&D, growing into a global healthcare enterprise. BC World Pharm is headquartered in Gyeonggi-do, Yeoju-si.